DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20174770

Evaluation of Osveral efficacy in reducing ferritin levels in patients with thalassemia major

Afshin Fathi, Majid Vafaie, Firouz Amani, Nadia Mohebbi

Abstract


Background: Beta thalassemia is one of the inherited blood diseases in which the production of specific chains in hemoglobin decreases. Esfarlal is a shaltor which is used in these patients as a single dose per day. Since it is prescribed orally, it is easier to tolerate the drug and control the serum iron level of the patient. The aim of this study was to evaluate the efficacy of Osveral in reducing ferritin levels in patients with thalassemia major.

Methods: This quasi-experimental study was performed on 48 patients with thalassemia major who referred to Bu-Ali hospital for receiving blood. At the beginning of the study, the required data were collected along with patients' tests including hemoglobin, ferritin, TSH, T4, CBC diff, BUN AST, ALT, BS and creatinine CBC diff. The Osveral drug was prescribed and the patients were evaluated monthly for up to 6 months on the basis of complications. In the first three months after the start of the drug, the serum ferritin level was measured, the dose was adjusted and 6 months after late, the previous tests were again requested, and the auditory and visual examinations were performed, and the information entered the checklist. Data were analyzed using SPSS statistical software.

Results: Among all patients, 27 (56.2%) were male and the rest were women with a mean age of 22.22 ± 8.77 years. The results showed that during one year of study, hemoglobin level increased and ferritin level decreased significantly, and other parameters didn’t show significant difference. Nausea and vomiting were the most common complications among patients, which was higher after Osveral than before receiving Osveral.

Conclusions: Results showed that Osveral is effective in reducing the level of ferritin in patients with thalassemia major, but control of hematuria is recommended when using this drug.


Keywords


Ferritin, Major thalassemia, Osveral

Full Text:

PDF

References


Weatherall DL, Clegg JB. Thalassemia: a global public health problem. Nat Med. 1996;2(8):847-9.

Najafipour F. Evaluation of endocrine disorders in patients with thalassemia major. Int J Endocrinol Metabol. 2008;6(2):104-13.

Fosburg M, Nathan DG. Treatment of Cooley's anemia. Blood. 1990;76:435-44.

Kliegman RM, Behrman RE, Jenson Hal B, Stanton Bonita F. Nelson Textbook of pediatrics. 8th ed. Philadelphia:Saunders; 2007:2034-2036.

Najafipour F, SariSorkhabi R, Zareizadeh M, Bahrami A, Ghoddousi K, Sorkhabi R, et al. Evaluation of Endocrine Disorders in Patients with Thalassemia Major. Iran J Endocrinol Metab. 2008;10:35-43.

Schwartz E, Benz EJ Jr. Thalassemia syndromes. In: Miller DR, Baehner RL, Smith CH, editors. Smith's Blood Diseases of Infancy and childhood. 6th ed. st. louis: Mosby; 1989:428-440.

Rezaei M, Poor Mahmoodi A, Ghaffarian Shirazi HR, Pakbaz F. Prevalence of diabetes mellitus in Thalassemic patients referring to Cooly’s centers of Kohgiloyeh and Boyerahmad. Armaghane-Dansh J Yasuj Unive Med Sci. 2004;9:42-35.

Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-73.

Gabutti V, Piga A. Results of long-term iron-chelating therapy.Acta Haematol. 1996;95:26-36.

Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. Eur J Clin Pharmacol. 2001;56:915-22.

Deferasirox. Available at: http://clinicaltrials.gov/ct2/results?term=deferasirox/ accessed on 6/17/2011

Deferasirox. Available at: http://www.exjade.com/index.jsp?lightbox=global-hcp/ accessed on 6/17/2011

Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with b-thalassemia. Blood. 2006;107:3455-62.

Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with betathalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82:458-65.

Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, et al. EPIC Study Investigators. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. haematologica. 2010;95.

Deferoxamine. Available at: http://www.osvahpharma.com/index.php?module=cdk&func=loadmodule&system=cdk&sismodule=user/content_view.php&sisOp=view&id=6&ctp_id=18&cnt_id=806www.fdo.ir/Drug/Fa/Downloads/ShowSection.aspx?fid=11/ accessed on 6/17/2011.

Eshghi P, Farahmandinia Z, Molavi M, Naderi M, Jafroodi M, Hoorfar H, et al. Efficacy and safety of Iranian made Deferasirox (Osveral®) in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study. DARU. 2011;19(3):35.

Keikhaei B. Sequential Deferoxamine - Deferasirox in Treatment of Major Thalassemia with Iron Overload; Iranian Journal of Pediatric Hematology and Oncology Vol1. No1.

Pourmovahed Z, Kalani Z, Salimi T, Kargar M. Investigating the Effects of Defroxamine Injection on Physical Growth in Children with Thalassemia Major. JSSU. 2012;20(2):194-200.

Rashidi GF, Kosaryan M, Karami H. Assessment of the effect of combination therapy with Deferiprone & Desferrioxamine on cardiac complications in major Thalassemia. J Mazandaran Univ Med Sci. 2007;17(61):12-9.

Molavi MA, Doozandeh, Nazemi AM, Evazi R, Mansoori F. Comparison of Therapeutic Response and Complications of Oral Osveral and Injection Desfereal Chelating Agent in Patient with Thalassemia Major. Asian J. Med. Pharm. Res, 2013;3(3):93-7.

Taher A, El-Beshlawy A, S. Elalfy M, Al Zir K, Daar SH, Habr D, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with b-thalassaemia: the ESCALATOR study. European Journal of Haematology. 2009;82:458-65.

Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107:3455-62.

Cassinerio E, Orofino N, Roghi A, Duca L. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. Blood Cells Mol Dis. 2014 Sep;53(3):164-7.

Jasim TA, Al-Wataify A, Tarish AH. A safety and efficacy of combination therapy of def erasirox and deferoxamine versus deferasirox for treatment of transfusional iron overload in sickle cell anemia in al-najaf and babylon province in iraq. Med. Res. Chron. 2014;1(1):04-10.

Arandi N, Haghpanah S, Safaei S, Zahedi Z, Ashrafi A, Eatemadfar P. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources. Transfus Med. 2015 Feb;25(1):8-12.

Piga A, Galanello R, Forni GL, Cappellini MD, Origa R. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873-80. PubMed: 16818273.

Haghpanah S, Zarei T, Zahedi Z, Karimi M. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia. Hematology. 2014;19(4):187-91.